Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Milestone Pharmaceuticals Q3 EPS $(0.34), Same YoY

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.

UBS Initiates Coverage On KB Home with Buy Rating, Announces Price Target of $67

By Benzinga Newsdesk

Today, 4:24 PM

UBS analyst John Lovallo initiates coverage on KB Home (NYSE:KBH) with a Buy rating and announces Price Target of $67.

KBH

Notable Upstart Holdings Insider Trades $41.95 Million In Company Stock

By Benzinga Insights

Today, 4:24 PM

Paul Gu, SVP And Product Data Science at Upstart Holdings (NASDAQ:UPST), made a large buy and sell of company shares on September 15, according to a new SEC filing.

UPST

Keybanc Maintains Overweight on Materion, Raises Price Target to $85

By Benzinga Newsdesk

Today, 4:24 PM

Keybanc analyst Philip Gibbs maintains Materion (NYSE:MTRN) with a Overweight and raises the price target from $82 to $85.

MTRN

Buckingham Maintains Buy on RenaissanceRe Holdings, Raises Price Target to $200

By Vick Meyer

Today, 4:24 PM

Buckingham maintains RenaissanceRe Holdings (NYSE:RNR) with a Buy and raises the price target from $192 to $200.

RNR

Milestone Pharmaceuticals Q3 EPS $(0.34), Same YoY

Related Posts

UBS Initiates Coverage On KB Home with Buy Rating, Announces Price Target of $67

Notable Upstart Holdings Insider Trades $41.95 Million In Company Stock

Keybanc Maintains Overweight on Materion, Raises Price Target to $85

Buckingham Maintains Buy on RenaissanceRe Holdings, Raises Price Target to $200